Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

NCT04858269 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT04858269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04858269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 27, 2021
Completion date
August 31, 2028
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head neck cancer, hypopharynx squamous cell carcinoma, larynx squamous cell carcinoma, metastatic squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma